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Abstract
ZBTB7A is frequently mutated in acute myeloid leukemia (AML) with t(8;21) translocation. However, the oncogenic
collaboration between mutated ZBTB7A and the RUNX1–RUNX1T1 fusion gene in AML t(8;21) remains unclear. Here,
we investigate the role of ZBTB7A and its mutations in the context of normal and malignant hematopoiesis. We demonstrate
that clinically relevant ZBTB7A mutations in AML t(8;21) lead to loss of function and result in perturbed myeloid
differentiation with block of the granulocytic lineage in favor of monocytic commitment. In addition, loss of ZBTB7A
increases glycolysis and hence sensitizes leukemic blasts to metabolic inhibition with 2-deoxy-D-glucose. We observed that
ectopic expression of wild-type ZBTB7A prevents RUNX1-RUNX1T1-mediated clonal expansion of human CD34+ cells,
whereas the outgrowth of progenitors is enabled by ZBTB7A mutation. Finally, ZBTB7A expression in t(8;21) cells lead to
a cell cycle arrest that could be mimicked by inhibition of glycolysis. Our findings suggest that loss of ZBTB7A may
facilitate the onset of AML t(8;21), and that RUNX1-RUNX1T1-rearranged leukemia might be treated with glycolytic
inhibitors.
Introduction
Recently, we and others found the transcription factor
ZBTB7A mutated in acute myeloid leukemia (AML) with
translocation t(8;21), at frequencies ranging from 9.4 to 23%
[1–6]. Hotspot mutations result either in loss (A175fs) or
alteration (R402) of the C-terminal zinc finger domain, which
is critical for DNA-binding of ZBTB7A [1]. The specific
association of ZBTB7A alterations with the t(8;21) subgroup
of AML patients points toward a unique mechanism of
leukemogenesis. While the RUNX1–RUNX1T1 fusion gene,
which results from the t(8;21) translocation, has been studied
extensively, it remains unclear how it may provide a fertile
ground for the acquisition of genetic lesions in ZBTB7A.
This oncogenic collaboration may arise from a com-
plementary action on perturbed hematopoietic development
(i.e., block of specific arms of the myeloid lineage).
Expression of full length RUNX1–RUNX1T1 in a murine
model does not cause leukemia [7, 8], but causes a partial
block of myeloid differentiation with suppression of ery-
thropoiesis and accumulation of immature granulocytes [9].
Interestingly, Zbtb7a has been described as a key regulator
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of hematopoietic differentiation with an essential role in
erythropoiesis [10], lineage choice of B vs T lymphopoiesis
[11] and long-term stem cell maintenance [12]. The invol-
vement of ZBTB7A in myeloid differentiation has so far not
been completely clarified, although Zbtb7a null mouse
studies showed a deficiency of mature myeloid cells in fetal
liver [12]. This suggests that ZBTB7A mutation could lead to
a block of terminal myeloid differentiation, collaborating with
RUNX1–RUNX1T1 to produce a complete differentiation
block.
Another way in which ZBTB7A mutation may collabo-
rate with RUNX1–RUNX1T1 is related to growth regulation
and metabolism. While expression of RUNX1–RUNX1T1
in stem cells causes increased proliferation [13], expression
in myeloid cell lines results in growth arrest. This growth
arrest is related to downregulation of MYC [14] and PKM2
[15]—a master regulator of glycolysis and a key enzyme of
the glycolytic pathway, respectively. Moreover, AML
t(8;21) has been described to depend on glycolytic meta-
bolism for its survival [16]. In turn, ZBTB7A can directly
repress the transcription of several genes implicated in gly-
colysis (SLC2A3, PFKP, and PKM) in an MYC-independent
manner, and ZBTB7A knockdown in a colon cancer cell line
resulted in increased glycolysis and proliferation [17].
ZBTB7A function in glycolysis regulation has so far not
been studied extensively in the hematopoietic system, but
the observed upregulation of glycolytic genes upon
ZBTB7A mutation in our patient cohort [1] may counteract
the growth arrest caused by RUNX1–RUNX1T1 in AML
t(8;21).
Considering that ZBTB7A plays a critical role both in
regulation of differentiation and cellular growth, alteration in
either of the two functions may contribute to RUNX1-
RUNX1T1-dependent leukemogenesis. In the present study,
we investigate the effect of ZBTB7A mutation on cellular
differentiation, glycolysis regulation, and RUNX1–RUNX1T1
directed cell expansion.
Results
ZBTB7A promotes granulopoiesis while blocking
monocytic differentiation
Since ZBTB7A is a key regulator of hematopoietic linage
fate decisions, we set out to compare the effect of ZBTB7A
wild type (WT) and mutants in the context of myeloid
differentiation. The cell line HL60 is a well-established
model for granulocytic and monocytic differentiation
[18, 19]. Therefore, we generated HL60 cells stably
expressing ZBTB7A WT or mutants. Granulocytic differ-
entiation induced by all-trans retinoic acid (ATRA) was
increased by ZBTB7A WT, while this effect was
significantly reduced for the mutants, with R402C showing
residual activity (Fig. 1a, Supplementary Fig. 1a). In con-
trast, monocytic differentiation induced by phorbol 12-
myristate 13-acetate (PMA) was reduced by ZBTB7A WT
but not by the mutants (Fig. 1b, Supplementary Fig. 1b). In
order to validate this effect, we generated an HL60
ZBTB7A knockout cell line. Interestingly, these cells pre-
sented a 5.5-fold increase in CD14 even without induction
of differentiation (Fig. 1c, Supplementary Fig. 1c). Ectopic
expression of ZBTB7A WT in the knockout cells restored
CD14 to the native levels, while expression of the mutants
had no effect (Fig. 1c, Supplementary Fig. 1d). With regard
to potential therapeutic applications, we tested the PMA
sensitivity of HL60 cells and found a significantly lower
IC50 in absence of ZBTB7A (mean (pM): 256.6 in KO vs
619 in control; p value= 0.0002) (Supplementary Fig. 1e).
We also observed that ZBTB7A WT expression lead to a
loss of transduced cells in HL60 without cell sorting (Fig.
1d).
Since ZBTB7A was previously described to promote
erythroid differentiation [10], we generated a K562
ZBTB7A knockout cell line (Fig. 1e). K562 cells can be
used as a model for erythroid differentiation [20]. As
expected, ZBTB7A knockout K562 cells presented a lower
erythroid differentiation (13.89 ± 2.8% reduction, p value=
0.0238) when compared with control cells (Fig. 1f, Sup-
plementary Fig. 1f). This impaired differentiation could be
rescued by ectopic expression of ZBTB7A WT but not by
the mutants (Fig. 1f, Supplementary Fig. 1g). These find-
ings confirm the observation that R402C and A175fs result
in loss of the regulatory function of ZBTB7A in myeloid
differentiation.
ZBTB7A blocks the differentiation of hematopoietic
stem and progenitor cells (HSPCs)
Considering that ZBTB7A was described to have a context-
dependent effect on cell differentiation (i.e., block or pro-
motion of differentiation) [21], we assessed the effect of
ZBTB7A mutations on the HSPC compartment. To this
aim, we generated human CD34+ cells stably expressing
ZBTB7A WT or mutants. Upon differentiation, we
observed a significant reduction of mature erythrocytes
(CD71+ CD235a+) in WT expressing cells, consistent with
previous reports [12]. In contrast, ZBTB7A mutant
expressing cells differentiated to a similar extent as the
control cells (Fig. 2a, b). When cells were differentiated to
granulocytes and monocytes, we observed that WT trans-
duced cells presented a reduction of CD15+ cells (corre-
sponding to decreased granulopoiesis). Again, cells
expressing the mutants did not exhibit this differentiation
block (Fig. 2c, d). A schematic representation of the effects
of ZBTB7A in differentiation is shown in Fig. 2e.
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Loss of ZBTB7A sensitizes to glycolysis inhibition
In order to study the effects of ZBTB7A on metabolism
described in other tissues [17], we analyzed transcriptomes
by RNA-Seq in K562 ZBTB7A knockout and control
clones (GSE140472). Differential expression analysis
revealed 1089 genes deregulated between the two settings
(adjusted p value < 0.05 and log-fold-change > 0.5) (Sup-
plementary Fig. 2a). Gene set enrichment analysis revealed
NOTCH3 transcriptional regulation as well as nutrient
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Fig. 1 ZBTB7A promotes granulopoiesis while blocking monocytic
differentiation. a HL60 cells stably expressing an empty vector (EV),
ZBTB7A WT or mutants were differentiated by ATRA treatment.
CD11b expression was assessed by flow cytometry. b HL60 cells
stably expressing ZBTB7A WT or mutants were differentiated by
PMA treatment. CD14 expression was assessed by flow cytometry.
c HL60 ZBTB7A KO and HL60 ZBTB7A KO stably expressing
ZBTB7A WT or mutants without induction of differentiation. CD14
expression was assessed by flow cytometry. d Competitive growth of
HL60 cells stably expressing ZBTB7A WT or mutants. e Western blot
from K562 cells, arrow indicates low levels of the ZBTB7A A175fs
mutant. f K562 ZBTB7A KO without induction of differentiation.
CD235a expression was assessed by flow cytometry. *p value < 0.05
compared with control cells.
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Fig. 2 ZBTB7A blocks the differentiation of HSPC. Flow cytometry measurements of human bone marrow CD34+ cells stably expressing
ZBTB7A WT or mutants are shown. a Representative results of cells primed for differentiation into erythrocytes using StemSpan Erythroid
Expansion Supplement for 7 days. b Summary of three independent experiments. c Representative results of cells primed for differentiation into
monocytes and granulocytes using HemaTox Myeloid Kit for 7 days. d Summary of three independent experiments. e Schematic representation of
the effects of ZBTB7A and RUNX1–RUNX1T1 expression on hematopoietic linage commitment.
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transport by solute carrier (SLC) proteins as the top sig-
nificantly affected gene ontologies (Fig. 3a).
As ZBTB7A was previously described to be a negative
regulator of glycolysis genes in colon cancer [17], we
focused on the expression of genes implicated in glycolysis.
This revealed an upregulation of the glucose transporters 1
(SLC2A1) and 3 (SLC2A3) in the knockout cells (Fig. 3b).
Interestingly, two glycolytic enzymes not previously
reported to be ZBTB7A targets were also found to be
upregulated in KO cells: phosphoglycerate mutase isoforms
2 and 3 (PGM2 and PGM3) responsible of converting 3-
phosphoglycerate into 2-phosphoglycerate, and Enolase 2
(ENO2) responsible for converting 2-phospho-D-glycerate
into phosphoenolpyruvate (Fig. 3b) (all comparisons p <
0.05). Other previously reported genes, such as PKM or
PKFP, were not significantly deregulated in this setting
(Supplementary Fig. 2b, c). The upregulated genes were
confirmed as ZBTB7A targets (Supplementary Fig. 3) using
publicly available ZBTB7A K562 ChIP-Seq data
(ENCSR000BME, ENCODE database).
Based on these data, we selected two KO clones to test
the functional impact of ZBTB7A loss on cellular meta-
bolism. In metabolic flux analyses, ZBTB7A KO cells
presented a slightly increased non-glycolytic acidification
(Supplementary Fig. 4a, b). ZBTB7A KO cells did not
show a statistically significant increase of glycolysis
upon glucose administration (Fig. 3c, Supplementary Fig.
4c), but they presented a higher glycolytic capacity after
inhibition of mitochondrial energy production compared
with control (Fig. 3c–e). Interestingly, the increased
energy demands of ZBTB7A KO cells could be com-
pensated by the upregulation of mitochondrial respiration
under glucose deprivation (Supplementary Fig. 4e). In
addition, we observed that knockout cells were more
sensitive to glycolysis inhibition with 2-deoxy-D-glucose
(2DG) compared with control cells (mean IC50 (mM):
8.03 in KO#1 and 5.05 in KO#2 vs 10.34 in control; p
values= 0.124 and 0.0005, respectively) (Fig. 3f). This
effect was also confirmed by long-term treatment, where
control cells were hardly affected by glycolysis inhibi-
tion, while knockout cells grew significantly slower
(Supplementary Fig. 4d). The differences observed
between the two KO clones tested may arise due to off-
target effects of the Cas9 treatment or due to the fact that
these lines were generated from single cells, amplifying
any preexisting differences in the cell of origin. However,
both clones show the same trends, namely, increased
glycolysis after mitochondrial shutdown and increased
sensitivity to glycolysis inhibition. In addition, we eval-
uated ex vivo sensitivity to 2DG in six different AML
patient-derived xenografts (PDX) models where we could
observe variable degrees of sensitivity (Supplementary
Fig. 5).
ZBTB7A prevents RUNX1-RUNX1T1-dependent
clonal expansion
Since ZBTB7A mutations are associated with AML t(8;21),
we assessed the interplay between ZBTB7A and the
RUNX1–RUNX1T1 fusion. To this aim, we used the
truncated version of RUNX1–RUNX1T1 (hereafter referred
to as RUNX1–RUNX1T1tr) that causes clonal expansion of
hCD34+ cells [13]. A scheme of the experimental setting is
provided in Fig. 4a. As expected, single positive cells
expressing RUNX1–RUNX1T1tr expanded, while single
positive cells expressing ZBTB7A WT or mutants did not
(representative experiment in Fig. 4b, replicates of this
experiment in Supplementary Fig. 6). Interestingly, cells
expressing both RUNX1–RUNX1T1tr and ZBTB7A WT
did not clonally expand and were quickly outcompeted by
RUNX1–RUNX1T1tr single positive cells. The clonal
expansion was enabled by the ZBTB7A mutations R402C
and A175fs. Upon coexpression of these mutants, double
positive cells expanded and no significant disadvantage
over the RUNX1–RUNX1T1tr single positive cells was
observed.
ZBTB7A causes cell cycle arrest
In order to elucidate if the prevention of RUNX1-
RUNX1T1tr-dependent clonal expansion by ZBTB7A
arises either from downregulation of glycolysis, enhanced
differentiation, or a combination of both effects, we
expanded hCD34+ cells using RUNX1–RUNX1T1tr for
60 days and then transduced them with ZBTB7A WT and
R402C. Cell-cycle analysis revealed that ZBTB7A WT
expressing cells show a significant G0/G1 arrest in detri-
ment of the S phase (Fig. 4c). In addition, we generated
Kasumi-1 cells stably expressing ZBTB7A WT or mutants.
We have previously shown that forced expression of
ZBTB7A WT in Kasumi-1 causes a growth disadvantage
[1]. Cell-cycle analysis revealed that ZBTB7A WT over-
expressing cells show G0/G1 arrest in detriment of the S
phase when compared with mutants and control (Fig. 4d).
When glycolysis was inhibited by 2DG treatment, control
cells showed a block of cell-cycle progression, reminiscent
of the effect caused by ZBTB7A WT overexpression
(Fig. 4d). At the same time, differentiation marker analysis
(CD11b, CD14, and CD15) did not show any significant
difference between the conditions tested (Supplementary
Fig. 7).
Discussion
ZBTB7A mutations in the context of AML have not yet been
extensively characterized. In the present study, we
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demonstrated that ZBTB7A mutations have a loss-of-
function phenotype with regard to differentiation and cell-
cycle regulation (Figs. 1a, b, 2 and 4c, d). Moreover,
ZBTB7A KO effects were only rescued by ectopic
expression of the WT form but not by the mutants (Fig. 1c,
f). We could though observe a slight residual activity of the
point mutant R402C (Fig. 1a), as already described in other
readouts [1]. Despite a previous report in the context of
colon cancer suggesting that ZBTB7A zinc finger mutations
act in a dominant negative manner [22], we could not find
any evidence for this effect in our models, even when the
expression of the R402C mutant was slightly higher than
the control (Fig. 1e). The fact that the mutation A175fs
results in an unstable truncated protein (Fig. 1e) also argues
for a loss-of-function mechanism. In addition, we showed
that the previously reported antiproliferative effect of
ZBTB7A [1] is not exclusive to the t(8;21) background, as
shown by loss of ZBTB7A WT expressing HL60 cells (Fig.
1d). This result is consistent with the assumption that
ZBTB7A acts as a tumor suppressor and with our obser-
vation that higher ZBTB7A expression levels correlate with
longer survival in cytogenetically normal AML patients [1].
Our results also corroborate a previously described role of
ZBTB7A in erythroid differentiation (Figs. 1f, 2a, b)
[10, 12] and suggest that ZBTB7A can block myeloid dif-
ferentiation of HSPC (Fig. 2c, d).
The most puzzling fact about ZBTB7A mutations in
AML is their exclusive presence in the context of core
binding factor leukemia, mainly in t(8;21) AML [1–6],
which suggests a specific collaboration between
RUNX1–RUNX1T1 and loss of ZBTB7A function. Of
note, it was previously reported that RUNX1–RUNX1T1
causes a block of the monocytic and erythrocytic linages in
favor of granulocytic differentiation in mouse and zebrafish
[9, 23]. In addition, an accumulation of neutrophils in the
bone marrow of mice was observed [24]. All these models
failed to present any leukemic disease. Interestingly, our
HL60 model indicates that ZBTB7A has a role in directing
cells into the granulocytic compartment while blocking
monocytic differentiation (Fig. 1a–c). A loss of ZBTB7A
function may therefore increase the block of myeloid dif-
ferentiation initiated by t(8;21) (Fig. 2e). These results are
in contrast to other reports based on cell lines stating that
RUNX1–RUNX1T1 is sufficient to completely block
granulocytic differentiation [25], however, such effect likely
depends on the cellular context. Furthermore, AML t(8;21)
was described to depend on glycolysis for its survival,
specifically depending on PFKP and SLC2A3 [16], both
direct targets of ZBTB7A [17]. This is further supported by
the fact that the t(8;21) translocation positive Kasumi-1 cell
line is highly sensitive to glycolysis inhibition [26]. In this
study, we show that loss of ZBTB7A increases the
expression of SLC glucose transporter genes as well as
ENO2, PGM2, and PGM3 (Fig. 3b), increasing glycolysis
(Fig. 3c) and sensitizing to glycolysis inhibition (Fig. 3f).
Interestingly, inhibition of mitochondrial respiration
demasked a profoundly increased glycolytic reserve in
ZBTB7A KO cells (Fig. 3e). This observation may
encourage further studies regarding a possible advantage for
ZBTB7A mutant cells in hypoxic environments. In vitro
treatment of PDX cells revealed different degrees of sen-
sitivity to 2DG (Supplementary Fig. 5), suggesting that
response might be variable between patients and may
depend on the genetic context. We also observed inter-
ference in RUNX1-RUNX1T1tr-dependent outgrowth of
hCD34+ cells by forced ZBTB7A expression (Fig. 4b,
Supplementary Fig. 6). Expression of ZBTB7A WT in a
t(8;21) rearranged background does not cause increased
differentiation in comparison to mutants (Supplementary
Fig. 7), however, it leads to a cell cycle arrest (Fig. 4c, d).
This effect resembles the cell cycle arrest due to the inhi-
bition of glycolysis through 2DG treatment (Fig. 4d). These
observations indicate that ZBTB7A expression in t(8;21)
leukemia may lead to a decreased glycolysis rate and cell
cycle arrest, thus impairing leukemia development. While
the translocation t(8;21) in AML was the first recurrent
cytogenetic abnormality ever described in any cancer [27], a
specific treatment for this entity is not yet available. This is
in contrast to other leukemia-associated rearrangements,
such as PML-RARA or BCR-ABL1, that are pharmacologi-
cally actionable [28, 29]. In the present study, we show that
ZBTB7A can counteract RUNX1-RUNX1T1-dependent
progenitor cell expansion through repression of glycolysis,
opening up avenues for a targeted treatment of AML t(8;21)
with metabolic inhibitors.
In summary, we have shown that ZBTB7A mutations
contribute to a terminal block of myeloid differentiation as
well as to deregulation of glycolysis. Further studies are
required to elucidate the complex interplay between tumor
metabolism and perturbed differentiation in myeloid
malignancies.
Methods
Plasmids and cell culture
All cell lines were acquired from DSMZ (Braunschweig,
Germany). HL60 and K562 were cultured in RPMI-1640
medium (Life Technologies, Darmstadt, Germany) with
10% fetal bovine serum (FBS) (Biochrom, Berlin, Ger-
many) and 1% PenStrep (PAN-Biotech, Aidenbach, Ger-
many). Kasumi-1 cells were cultured with RPMI-1640
medium, 1% PenStrep and 20% FBS.
Human bone marrow CD34+ cells, containing HSPCs,
were purchased from Lonza (Cologne, Germany) and
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cultured using IMDM (GE Healthcare Life Sciences,
Pasching, Austria) complemented with 20% FBS 2% glu-
tamine, 100 U PenStrep, 20 ng/ml FLT3-l, 20 ng/ml GM-
CSF, hIL-3 10 ng/ml, hIL-6 20 ng/ml, hSCF 20 ng/ml,
hTPO 20 ng/ml all from Peprotech (Hamburg, Germany).
PDX were described before [30]. Briefly, cells were
isolated from NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
bone marrow and then cultured in StemPro-34 SFM Med-
ium (StemCell Technologies, Grenoble, France) supple-
mented with 1% PenStrep, 1% L-Glutamine, 2% FBS and
10 ng/ml SCF, TPO and IL-3.
The pMSCV-IRES-GFP ZBTB7A WT, R402C, and
A175fs were described before [1]. The pMSCV-RUNX1-
RUNX1T1tr-IRES-tdTomato was described before [31].
pSpCas9(BB)-2A-GFP (px458) is available from Addgene
(Plasmid #48138) and gRNA sequences targeting ZBTB7A
(GACTCGAGGTACTCCTTGGCG or GCCGCCGCT
GCCAGCTTCCCG) were cloned as described before [32].
CRISPR/Cas9 knockout
K562 and HL60 cells were electroporated with px458
containing a gRNA targeting ZBTB7A or an empty vector
using Lonza 2b electroporation system following the man-
ufacturer’s recommendation. Single cells were sorted for
GFP into a 96-well plate. Single cells were expanded and
ZBTB7A status was assessed by Western blot and Sanger
sequencing, respectively.
Differentiation assays
Cells were transduced and sorted for GFP. Granulocytic dif-
ferentiation of HL60 cells was induced with 2 µM ATRA
treatment (Sigma-Aldrich, Taufkirchen, Germany) for 72 h
followed by flow cytometry measurement of CD11b surface
expression using a mouse PE-Cy7 anti-human CD11b anti-
body (clone: ICRF44, BD Biosciencies, Temse, Belgium).
Monocytic differentiation of HL60 cells was induced with
0.5 nM PMA (Abcam, Cambridge, UK) treatment for 48 h
followed by flow cytometry measurement of CD14 surface
expression using a mouse PE-Cy7 anti-human CD14 anti-
body (clone: M5E2, BD Biosciencies). Erythroid differentia-
tion of K562 was assessed by flow cytometry measurement of
glycophorin A (CD235a) surface expression using a mouse
PE anti-human glycophorin A antibody (clone: GA-R2, BD
Biosciencies) without induction of differentiation.
A total of 5000 Human CD34+ bone marrow cells were
seeded either in StemSpan SFEM with StemSpan Erythroid
Expansion Supplement or HemaTox Myeloid Kit (StemCell
Technologies) in a 96-well plate. Cells were incubated for
7 days and differentiation was assessed by flow cytometry.
Erythroid differentiation potential was assessed as stated
before and with an additional mouse APC anti-human
CD71 antibody (clone: M-A712, BD Biosciencies). Granu-
locytic differentiation was assessed by a mouse APC anti-
human CD15 antibody (clone: SSEA-1, Biolegend, London,
UK) and monocytic differentiation as stated above.
Metabolic flux analysis
In all, 8 × 104 cells were plated with Seahorse XF RPMI
medium, pH 7.4 in a XF96 cell culture microplate (both
Agilent, Waghauesel-Wiesental, Germany) coated with Cell
Tak (Corning, Berlin, Germany) according to the manu-
facturer’s instructions. Oxygen consumption rate (OCR)
and extracellular acidification rate (ECAR) were measured
at 37 °C using a Seahorse XFe96 Analyzer (Agilent). Three
measurements of OCR and ECAR were taken before and
after each sequential injection of glucose at a final con-
centration of 1 mM, rotenone/antimycin A (Rot/AA) at a
final concentration of 0.5 µM and 2DG at a final con-
centration of 50 mM (all Agilent).
Drug sensitivity assays
In all, 104 cells were plated in a 96-well plate with
increasing concentrations of 2DG or PMA in technical
triplicates. Cells were incubated for 72 h and then viability
was assessed using CellTiter-Blue Cell Viability Assay
(Promega, Mannheim, Germany) following the recom-
mended protocol.
Human CD34+ cells competitive growth
Human CD34+ bone marrow cells were double transduced
with constructs harboring ZBTB7A WT, R402C, or A175fs
(marked with GFP) together with RUNX1–RUNX1T1tr
(marked with tomato). Expansion of single and double
fluorescent marker-positive cells was then followed by flow
cytometry over 60 days after transduction as described
before [31].
Cell-cycle analysis
Kasumi-1 and hCD34 cells were transduced and 4 × 105
cells harvested and resuspended in 500 µl PBS. DRAQ5
(Thermo Fisher Scientific, Darmstadt, Germany) was added
at a final concentration of 5 µM and incubated for 15 min.
Cells were then analyzed by flow cytometry gating for GFP-
positive cells and single events.
Statistical analysis
P values were calculated using two-tailed Student’s t test
for single comparison and analysis of variance followed
by Dunnett’s multiple comparisons test for multiple
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comparisons in GraphPad Prism 7.03 (GraphPad Soft-
ware, Inc., San Diego, CA, USA). Similarity of variance
was evaluated using the Brown–Forsythe test. Graphs
show mean and standard deviation of the mean of three
independent experiments unless stated otherwise. Asterisk
indicates significant differences (p value < 0.05). Sample
exclusion was not carried out. FACS results were analyzed
with FlowJo v10 (FlowJo LLC, Ashland, OR, USA).
Data availability
The RNA-Seq data from K562 ZBTB7A knockout cells
supporting the findings of this study is available in the Gene
Expression Omnibus repository, GEO accession:
GSE140472.
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